Loading

Daré Bioscience

June 16, 2025
Company Presentation
Reproductive/Sexual Health
Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. We believe that innovation does not have to start from scratch. Our goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products we identify, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that we leverage. This gives us optionality and flexibility, in many cases, in how we seek to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner.
Daré Bioscience
Company HQ City: San Diego
Company HQ State: CA
Company HQ Country: United States
Year Founded: 2015
Lead Product in Development: Commercial - XACIATO Launching 2025 - Sildenafil Cream Phase 3 - Ovaprene hormone-free investigational contraceptive

CEO

Sabrina Martucci Johnson

Development Phase of Lead Product

Multiple Products in Market

Number of Unlicensed Products Looking for Licensing

8

Exchange

NASDAQ

Ticker

DARE

When you expect your next catalyst update?

Sildenafil Cream launch 4Q-2025; Ovaprene interim Phase 3 DSMB mid-2025

What is your next catalyst (value inflection) update?

quarterly updates with SEC filings - next update May 2025
Visit Website
Primary Speaker
Sabrina Johnson
Sabrina Johnson
President and CEO
Daré Bioscience

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS